Compare SUIG & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SUIG | VYGR |
|---|---|---|
| Founded | 2006 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.0M | 222.4M |
| IPO Year | N/A | 2015 |
| Metric | SUIG | VYGR |
|---|---|---|
| Price | $1.21 | $3.39 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $5.75 | ★ $17.00 |
| AVG Volume (30 Days) | ★ 748.1K | 631.7K |
| Earning Date | 03-09-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,608,807.00 | ★ $31,316,000.00 |
| Revenue This Year | $47.71 | N/A |
| Revenue Next Year | $42.04 | $71.77 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.58 | N/A |
| 52 Week Low | $1.13 | $2.65 |
| 52 Week High | $8.66 | $5.55 |
| Indicator | SUIG | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 29.52 | 36.03 |
| Support Level | $1.17 | $3.36 |
| Resistance Level | $1.33 | $3.91 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 10.00 | 12.58 |
Sui Group Holdings Ltd is a non-bank lender and specialty finance company. The company is engaged in the business of providing short-term specialty finance solutions to private businesses, micro-and small-cap public companies, and high-net-worth individuals. The principal specialty finance solutions that the group provides are high-interest short-term lending arrangements. Typically, these lending arrangements involve obtaining collateral as security for the borrower's repayment of funds, or personal guarantees from the principals or affiliates of the borrower.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.